Q1 2019 Xvivo Perfusion AB Earnings Call Transcript
Ladies and gentlemen, welcome to XVIVO Perfusion Q1 Report 2019. Today, I'm pleased to present CEO, Magnus Nilsson; and CFO, Christoffer Rosenblad.
(Operator Instructions)
Please go ahead with your meeting.
()-&
Thank you very much, and welcome to the XVIVO Perfusion Q1 report. I'm Magnus Nilsson, and again, I have Christoffer Rosenblad on my side. You have to excuse me, I caught a cold on my way here the other day from the United States. So I hope that you can hear my voice good.
Let's go to Slide #2, highlights from '19 Q1. Reimbursement process for EVLP approved in France. We see very encouraging results from the first 6 patients in the lung study with the heart preservation device. It was presented at the yearly -- the annual heart and lung transplant congress with great interest. We also have presented this device for thought-leading heart transplant surgeons worldwide, and they've shown a great interest in starting clinical trials
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |